8S-Lipoxygenase (8S-LOX) is known as a mouse homolog of human 15S-LOX-2. 15S-LOX-2 was downregulated in malignant transformation of prostate epithelial cells, and its overexpression caused cell cycle arrest. To determine whether 8S-LOX would have a growth inhibitory effect on prostate carcinoma, we obtained human prostate carcinoma PC-3 cells expressing 8S-LOX or 15S-LOX-2. The growth rate of cells measured by colorimetric assay was reduced by expression of 8S-LOX and 15S-LOX-2. The addition to enzyme-expressing cells of arachidonic acid enhanced the growth suppressive effect, whereas the expression of catalytically inactive mutants did not affect cell growth, suggesting that the effect was product-dependent. DNA microarray and quantitative reverse transcription-PCR analyses revealed that the c-myc mRNA coding region determinant-binding protein/insulin-like growth factor II mRNA-binding protein 1 (CRD-BP/IMP-1), known as an oncofetal protein, was down-regulated in 8S-LOXand 15S-LOX-2-expressing PC-3 cells. Targeted knockdown of CRD-BP/IMP-1 resulted in inhibition of the DNA synthesis rate of PC-3 cells as measured by bromodeoxyuridine incorporation. We propose that expression of 8S-LOX and 15S-LOX-2 suppresses CRD-BP/IMP-1 expression, resulting in inhibition of human prostate carcinoma PC-3 cell proliferation.
8S-Lipoxygenase (8S-LOX) is a dioxygenase cloned from phorbol ester-treated mouse skin. 1, 2) The enzyme preferentially oxygenates arachidonic acid, producing 8S-hydroperoxyeicosatetraenoic acid (8S-HPETE) as the primary product, which is subsequently metabolized to 8,15-diHPETE and 8,9-leukotriene A 4 by the enzyme itself as well as to 8S-hydroxyeicosatetraenoic acid (8S-HETE) by cellular peroxidases. 3, 4) 8S-LOX shows 78% amino acid sequence identity to 15S-LOX-2 cloned from human skin 5) and is considered to be a mouse homolog of the human enzyme. 6, 7) The pathophysiological function of 8S-LOX was suggested by a report showing that abundant expression of 8S-LOX mRNA occurred in reversible papilloma of mouse skin, whereas expression of the message in carcinoma was below the level of detection by Northern blot analysis. 8) Skin-targeted 8S-LOX transgenic mice showed decreased tumor multiplicity as compared with wild-type mice after phorbol ester treatment, suggesting that 8S-LOX has an antitumorigenic effect, although there was no significant difference in tumor incidence or carcinoma formation between wild-type and transgenic mice.
9) 8S-HETE was reported to have the ability to induce keratinocyte differentiation through selective activation of peroxisome proliferator-activated receptor (PPAR)-in primary keratinocytes. 10) On the other hand, 15S-LOX-2 presented in normal human prostate epithelial cells as well as benign prostate tumors, whereas the expression level of the enzyme decreased in malignant transformation of the cells. 11) Overexpression of 15S-LOX-2 in human prostate carcinoma PC-3 cells caused cell-cycle arrest, and the responsible product was reported to be 15S-HETE as a ligand for PPAR-. 12, 13) However, there is a report indicating that 15S-LOX-2 as y To whom correspondence should be addressed. Tel/Fax: +81-866-94-2155; E-mail: ytaka@fhw.oka-pu.ac.jp Abbreviations: ANOVA, analysis of variance; BrdU, bromodeoxyuridine; CRD-BP/IMP-1, c-myc mRNA coding region determinant-binding protein/insulin-like growth factor II mRNA-binding protein 1; Cy, Cyanine; FBS, fetal bovine serum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HODE, hydroxyoctadecadienoic acid; H(P)ETE, hydro(pero)xyeicosatetraenoic acid; LOX, lipoxygenase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; PPAR, peroxisome proliferator-activated receptor; qRT-PCR, quantitative reverse transcription-PCR; siRNA, short interfering RNA well as its splice variants having no arachidonic acidmetabolizing activity suppressed PC-3 tumor growth, suggesting that the tumor-suppressive function did not necessarily depend on the catalytic activity of the enzyme. 14) Recently it was reported that inducible expression of 15S-LOX-2 and 8S-LOX inhibited growth of premalignant mouse keratinocyte cell line 308. 15) To identify the modification in gene expression responsible for LOX-mediated tumor suppression, we developed PC-3 cells expressing 8S-LOX or 15S-LOX-2 in a doxycycline-inducible manner, and found that the growth of PC-3 cells was suppressed by expression of these lipoxygenases. We employed DNA microarray to compare the expression patterns of the genes simultaneously between doxycycline-induced and noninduced cells. Of the 18,000 genes represented on the chip, we focused on c-myc mRNA coding region determinantbinding protein/insulin-like growth factor II mRNAbinding protein 1 (CRD-BP/IMP-1), whose expression was significantly lower in the 8S-LOX-expressing cells.
CRD-BP/IMP-1 is an RNA binding protein that recognizes RNAs, including c-myc mRNA instability elements 16) and the 5 0 -untranslated region of leader 3 0 IGF-II mRNA. 17) CRD-BP/IMP-1 is expressed in fetal and neonatal mammals and in some tumors, whereas its expression is reduced or absent in normal adult tissues. [17] [18] [19] [20] [21] [22] [23] Overexpression of CRD-BP/IMP-1 in mammary epithelial cells of adult transgenic mice induces mammary tumors.
24) The present study indicates that CRD-BP/IMP-1 is one of the critical regulators in LOX-mediated suppression of human prostate carcinoma PC-3 cell proliferation.
Materials and Methods
Materials. Arachidonic and linoleic acids were purchased from Nu-Chek Prep (Elysian, MN), a BigDye terminator cycle sequencing kit version 1.1 was from Applied Biosystems (Foster City, CA), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), RPMI1640 medium and soybean lipoxygenase (type I) were from Sigma (St. Louis, MO), doxycycline was from Nacalai (Kyoto, Japan), ECL Western blotting detection reagents were from GE Healthcare (Piscataway, NJ), Ex Taq DNA polymerase was from Takara Bio (Shiga, Japan), fetal bovine serum (FBS) was from JRH Biosciences (Lenexa, KS), lipofectamine, lipofectamine 2000, TA cloning vector pCR2.1 and SuperScript III reverse transcriptase were from Invitrogen (Carlbad, CA), a MicroBCA protein assay kit was from Pierce (Rockford, IL), reagents for bromodeoxyuridine (BrdU) cell proliferation assay was from Exalpha Biological (Watertown, MA), restriction enzymes were from Toyobo (Osaka, Japan), and RNeasy spin columns were from Qiagen (Valencia, CA). A rabbit polyclonal antibody against human 15S-LOX-2 that cross-reacted with murine 8S-LOX and cDNA for human 15S-LOX-2 were gifts of Dr. Alan R. Brash of Vanderbilt University. Human prostate carcinoma PC-3 cells were kindly provided by Dr. Atsushi Mizokami of Kanazawa University. 13S-Hydroxyoctadecadienoic acid (13S-HODE) and 15S-HETE were prepared by incubation of soybean LOX with linoleic acid and arachidonic acid respectively, as described previously. 25) 8S-HETE was prepared by incubation of arachidonic acid with recombinant purified 8S-LOX expressed in E. coli, as described elsewhere. 26) Cell culture. PC-3 cells were maintained at 37 C with 5% CO 2 in RPMI1640 supplemented with 10% FBS without antibiotics. The cells were subcultured every 3-4 d using a standard trypsin protocol.
Plasmid. Doxycycline-regulated expression vector pOSTet14mcs (Miwa et al., manuscript in preparation) was constructed using pEB6CAGMCS 27) carrying on Epstein-Barr virus replication origin, oriP, and a replication initiation factor (EBNA-1) that were sufficient for autonomous replication in human cells. pOSTet14mcs also encoded a tetracycline-dependent transactivator (rtTA2 S -M2). 28) Murine 8S-LOX cDNA covering the entire coding sequence was isolated from a mouse skin cDNA library using PCR with Ex Taq DNA polymerase. 26) Catalytically inactive mutants of 8S-LOX in which His374 or His379 was replaced by Leu (H374L and H379L) were synthesized by site-directed mutagenesis, as described previously.
3) Murine 8S-LOX cDNA and its mutants as well as 15S-LOX-2 5) in the sense and antisense directions were subcloned into the EcoRI site of pOSTet14mcs. The nucleotide sequences were confirmed using an Applied Biosystems 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA) with a BigDye terminator cycle sequencing kit. The expression plasmids were introduced into PC-3 cells using lipofectamin according to the manufacturer's instructions. After 24 h, transfected cells were selected by incubating the cells in RPMI1640 medium containing 10% FBS and geneticin at 500 mg/ml for 7 d. Doxycycline at 1 mg/ml was added for enzyme induction.
Enzyme assay. The enzyme activity of the 8S-LOX-and 15S-LOX-2-expressing PC-3 cells was determined as described previously. 3, 26) Briefly, the cells were sonicated twice each for 5 s on ice in 50 mM Tris-HCl (pH 7.4) containing 1 mM EDTA, and incubated with 25 mM arachidonic acid in a 200-ml reaction mixture of 100 mM Tris-HCl (pH 7.4) at 37 C for 45 min. The products were reduced by the addition of glutathione peroxidase (0.1 units) and 5 mM GSH, followed by incubation for further 10 min. After acidification of the reaction mixture to pH 2-3 by the addition of 1 M hydrochloric acid, 0.5 nmol of 13S-HODE was added as an internal standard. Lipids were extracted by diethyl ether and analyzed by reverse-phase HPLC continuously monitoring UV absorption at 235 nm. HPLC was carried out using a TSK ODS-120T column (250 mm Â 4:6 mm, 5mm particle size, Tosoh, Tokyo) with a solvent system of methanol/water/acetic acid (80:20:0.01, by vol.) at a flow rate of 1 ml/min. The protein concentration was determined using a MicroBCA kit with bovine serum albumin as the standard.
Western blotting. The cells were sonicated twice each for 5 s on ice in 50 mM Tris-HCl (pH 7.4) containing 1 mM EDTA. The sonicate (20 mg of protein) was subjected to 10% SDS-polyacrylamide gel electrophoresis and electrophoretically transferred to a polyvinylidene difluoride membrane. After blocking with 10% nonfat dry milk in 20 mM Tris-HCl (pH 7.4) containing 136 mM NaCl and 0.1% Tween 20, the membrane was incubated for 1 h with an anti-15S-LOX-2 antibody at 1:1,000 dilution. 8S-LOX, its mutants, and 15S-LOX-2 were visualized with a peroxidase-labeled anti-rabbit IgG antibody and ECL Western blotting detection reagents according to the manufacturer's instructions.
Cell proliferation assays. Cell proliferation was measured by MTT assay, as described previously. 29) Briefly, PC-3 cells transfected with expression plasmids were cultured in a 96-well plate at 5 Â 10 3 cells/well in RPMI1640 containing 10% FBS and 500 mg/ml of geneticin in the presence and the absence of 1 mg/ml of doxycycline. The medium was removed after the indicated times, and 100 ml of MTT solution containing 50 mg of MTT in RPMI1640 (0.5 mg/ml of MTT in RPMI1640) was added to the well. After 4 h of incubation at 37 C, 100 ml of isopropanol containing 0.04 M HCl was added and mixed in thoroughly. After several min, the absorbance at 570 nm was measured with a reference wavelength of 630 nm using Bio-Rad microplate reader model 680 (Bio-Rad, Hercules, CA).
To measure the DNA synthesis rate of the cells, transfected cells were cultured in a 96-well plate at 1 Â 10 3 cells/well in RPMI1640 containing 10% FBS and 500 mg/ml of geneticin in the presence and the absence of 1 mg/ml of doxycycline. After the indicated periods, the cells were pulse-labeled for 12 h with 60 mM BrdU in the same medium. BrdU incorporation was quantified using a BrdU cell proliferation assay kit according to the manufacturer's instructions. The results were corrected by the viable cell number, which was simultaneously determined by MTT assay.
DNA microarray. Total RNA was isolated from 8S-LOX-expressing cells and cells without doxycycline treatment using an RNeasy spin column. Synthesis of cDNA using Molony-murine leukemia virus reverse transcriptase followed by Cyanine 3 (Cy3)-or Cy5-labeled cRNA synthesis using T7 RNA polymerase were performed with the low RNA input fluorescent linear amplification system following the instructions recommended by Agilent Technologies (Palo Alto, CA). Equivalent amounts of Cy3-cRNA and Cy5-cRNA were combined and hybridized to a microarray slide (Human 1A Oligo Microarray version 2, Agilent) in Agilent hybridization buffer for 17 h at 60 C according to the manufacturer's instructions. The slide was washed with 6 Â SSC containing 0.005% Triton X-102 for 10 min at room temperature and 0:1 Â SSC containing 0.005% Triton X-102 at 4 C. The hybridized slide was scanned using an Agilent DNA microarray scanner at 10 mm resolution. Image analysis was performed with Agilent Feature Extraction 9.1 Software. Saturated and blemished spots, which were less than 0.5% of total spots, were flagged and excluded from analysis. Spots whose signal of neither Cy3 nor Cy5 was significantly higher than background were also excluded. Ratios between mean net fluorescence from the Cy3 channel and mean net fluorescence from the Cy5 channel were calculated for each spot. Genes that were induced or repressed more than 4-fold with statistically significance (p < 0:01) were considered.
Quantitative reverse transcription-PCR analysis. Expression of CRD-BP/IMP-1 mRNA was evaluated by quantitative reverse transcription-PCR (qRT-PCR) analysis. Total RNA was isolated from transfected cells using an RNeasy spin column (Qiagen, Valencia, CA) according to the manufacturer's protocol. First-strand cDNA was synthesized using SuperScript III reverse transcriptase and oligo(dT) 20 as primer. qRT-PCR analyses were performed using a Bio-Rad iQ5 real time PCR detection system. The CRD-BP/IMP-1-specific primers were upstream, 5 0 -TCCCCACCCACCCTCTAATGGAC-3 0 , and downstream, 5 0 -AAGTGGAGCTGCCACTACCTAAT-3 0 , resulting in a 107-bp product. The primer sequences for housekeeping glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were upstream, 5
0 -ATGA-GAAGTATGACAACAGCCTCAAG-3 0 , and downstream, 5 0 -TCAT-GAGTCCTTCCACGATACCAAAG-3 0 , generating a 117-bp product. A qRT-PCR mixture (25 ml) contained 1 ml of template cDNA, 0.2 mM each primer, and 12.5 ml of iQ SYBR Green Supermix (Bio-Rad). The cycling protocol consisted of 95 C for 3 min and 40 cycles of denaturation at 94 C for 30 s, annealing at 60 C for 30 s, extension at 72 C for 30 s, and plate read. To confirm the amplification specificity, the amplified products were analyzed by 3% agarose gel electrophoresis. We also performed a melting curve analysis at the end of cycling. The nucleotide sequences of the PCR products were confirmed using an Applied Biosystems 3130 Genetic Analyzer with a BigDye terminator cycle sequencing kit. All the samples were analyzed for GAPDH expression in parallel in the same run. Analysis of the qRT-PCR was done by the ÁCt cycle threshold method (ÁCt ¼ CtðCRP-BP=IMP-1Þ À CtðGAPDHÞ). Relative gene expression was obtained by ÁÁCt methods (ÁÁCt ¼ ÁCtðsampleÞ À ÁCtðcontrolÞ). The difference in the expression levels was determined according to the formula 2 ÀÁÁCt .
30)
Short interfering RNA (siRNA). Twenty-one nucleotide doublestranded RNAs directed against CRD-BP/IMP-1 were designed (GenBankÔ accession no. NM 006546) and chemically synthesized by Qiagen (Valencia, CA). The sense and antisense sequences were CRD-BP-si1, r(GGCCCAUAAUAACUUUGUA)dTdT and r(UAC-AAAGUUAUUAUGGGCC)dTdT, and CRD-BP-si2, r(GAAUCUA-UGGCAAACUCAA)dTdT and r(UUGAGUUUGCCAUAGAUUC)-dTdT. The siRNA sequences were subjected to a BLAST search against human genome sequences in GenBank to confirm specificity. Control non-silencing siRNA that had no known homology with mammalian genes was purchased from Qiagen. The sense and antisense sequences were r(UUCUCCGAACGUGUGACGU)dTdT and r(ACGUGACACGUUCGGAGAA)dTdT. All siRNAs were diluted to a final concentration of 20 mM in 30 mM HEPES-KOH (pH 7.4) containing 100 mM potassium acetate and 2 mM magnesium acetate, and stored in aliquots at À80 C. The day before transfection, PC-3 cells were plated at a density of 5 Â 10 4 cells in a 35-mm dish. Transient transfection of siRNAs was carried out using 5 ml of lipofectamine 2000 and a final concentration of 40 nM siRNA, following the manufacturer's instructions.
Statistical analysis. Experimental data are shown as means AE SD. Statistical analysis was performed by one-way analysis of variance (ANOVA), followed by Tukey's HSD or Dunnett's post hoc test.
Results

Doxycycline-induced expression of 8S-LOX and 15S-LOX-2 in human prostate carcinoma PC-3 cells
Expression plasmid in which 8S-LOX or 15S-LOX-2 was induced in a doxycycline-inducible manner was introduced into human prostate carcinoma PC-3 cells. The cells, harvested 48 h after doxycycline addition, were sonicated and incubated with arachidonic acid. The products were separated by reverse-phase HPLC monitoring absorption at 235 nm. As shown in Fig. 1A , sonicated cells treated with doxycycline generated a peak which co-chromatographed with authentic 8S-HETE or 15S-HETE, whereas untreated cells hardly generated the products. The expression of 8S-LOX and 15S-LOX-2 proteins in doxycycline treated cells was confirmed by Western blotting using an antibody raised against 15S-LOX-2, whereas the enzymes were hardly detected in untreated cells (Fig. 1B) . The specific enzyme activities of the sonicate prepared from 8S-LOX-and 15S-LOX-2-expressing cells were 1:7 AE 0:2 and 21:3 AE 1:4 nmol/45 min/mg of protein respectively (n ¼ 6). Control cells transfected with plasmid in which the cDNA for the enzyme was ligated in the reverse direction (antisense control) did not oxygenate the substrate (data not shown) or express the enzyme protein (Fig. 1B) . As shown in Fig. 1C , the enzyme activity reached a maximum at 48 h after doxycycline treatment and gradually decreased thereafter, for unknown reasons. The results indicate that doxycycline induced catalytically active enzymes in PC-3 cells.
Growth suppression of PC-3 cells by 8S-LOX and 15S-LOX-2 overexpression
We examined the growth rate of transfected cells by MTT assay. As shown in Fig. 2A , the number of viable cells significantly decreased, by 30 AE 1% and 17 AE 1% at day 8, after doxycycline-dependent induction of 8S-LOX and 15S-LOX-2 respectively, as compared with cells without doxycycline. To confirm that the 8S-LOX-expressing cells that showed less enzyme activity than 15S-LOX-2-expressing cells inhibited the growth rate of PC-3 cells more efficiently, we compared the growth rate of these cells simultaneously. The number of 8S-LOX-expressing cells assessed by MTT assay was 79 AE 3% as compared with 15S-LOX-2-expressing cells 8 d after doxycycline treatment, significantly lower than that of the 15S-LOX-2-expressing cells (p < 0:01). The growth rate of cells transfected with antisense controls was not changed by doxycycline treatment. The DNA synthesis rate was quantified by BrdU incorporation into the cells. As shown in Fig. 2B , BrdU incorporation corrected by the viable cell number measured by MTT assay significantly decreased, by 48 AE 4% and 33 AE 6% in 8S-LOX-and 15S-LOX-2-expressing cells respectively, at 48 h after the induction of enzymes as compared with the untreated cells (p < 0:01). These results indicate that expression of 8S-LOX and 15S-LOX-2 suppressed the growth rate of PC-3 cells.
Growth suppression of PC-3 cells by 8S-LOX required its catalytic activity
To determine whether 8S-LOX would require the catalytic activity of the enzyme to suppress cell growth, a plasmid expressing mutated 8S-LOX (H374L and H379L) with no enzyme activity in a doxycyclinedependent manner was introduced into PC-3 cells. As shown in Fig. 2C , doxycycline-dependent induction of H374L did not suppress the growth rate, while the same level of the enzyme protein was expressed in the cells (Fig. 1B) . Essentially identical results were obtained with another mutated enzyme (H379L, data not shown). We examined the effect of arachidonic acid treatment on the growth rate of 8S-LOX-and 15S-LOX-2-expressing cells. As shown in Fig. 2C , the addition of arachidonic acid at 5 mM enhanced the growth inhibitory effect on the cells due to the expression of 8S-LOX and 15S-LOX-2, while the same treatment showed no effect due to H374L expression. The growth rate of the 8S-LOXexpressing cells treated with arachidonic acid fell by 48 AE 6% as compared with the cells without doxycycline, and was significantly lower than that of the cells without arachidonic acid (p < 0:01). Similarly, the growth rate of the 15S-LOX-2-expressing cells was suppressed by 32 AE 5% when treated with arachidonic acid, a level significantly lower than that of the untreated cells (p < 0:01). The addition of arachidonic acid did not affect the growth of inactive mutant-expressing cells or antisense-control cells. Linoleic acid had no effect on the growth rate when added to wild-type 8S-LOXexpressing cells (data not shown).
8S-LOX and 15S-LOX-2 suppressed CRD-BP/IMP-1 expression
We compared the global transcription pattern in doxycycline-treated PC-3 cells expressing 8S-LOX with non-treated cells by DNA microarray. Of 18,000 genes analyzed, human CRD-BP/IMP-1 was down-regulated in the 8S-LOX-expressing cells. The level of CRD-BP/ IMP-1 gene expression in the 8S-LOX-expressing cells was 4.5 to 5.7-fold lower than in non-treated cells. In contrast, we did not find genes up-regulated by more than 3-fold in the 8S-LOX-expressing cells. To confirm these data, we examined the level of CRD-BP/IMP-1 mRNA in 8S-LOX-expressing cells by qRT-PCR analysis. Doxycycline-induced expression of 8S-LOX decreased the level of CRD-BP/IMP-1 mRNA by 70 AE 17% at 48 h after induction of the enzyme as compared with doxycycline-untreated cells (p < 0:05) (Fig. 3) . Doxycycline-dependent induction of H374L did not change the CRD-BP/IMP-1 mRNA level, indicating that enzyme activity was required for down-regulation of the gene. CRD-BP/IMP-1 expression also decreased, by 47 AE 12%, in the 15S-LOX-2-induced PC-3 cells (p < 0:05). Northern blot and Western blot analysis did not detect CRD-BP/IMP-1, probably because the expression level of the gene was below the detection limit of these analyses (data not shown). Consequently, expression of CRD-BP/IMP-1 mRNA was suppressed by doxycycline-induced expression of 8S-LOX and 15S-LOX-2 in the PC-3 cells.
Targeted knockdown of CRD-BP/IMP-1 suppressed proliferation of PC-3 cells
To examine the roles of CRD-BP/IMP-1 in PC-3 growth, we employed RNA interference for CRD-BP/ IMP-1 gene silencing in PC-3 cells. PC-3 cells were transfected with two chemically synthesized siRNAs directed against CRD-BP/IMP-1 mRNA (CRD-BP-si1 and CRD-BP-si2). Total RNA was extracted 48 h after transfection, and the expression levels of CRD-BP/ IMP-1 mRNA were analyzed using a qRT-PCR system. As shown in Fig. 4A , the CRD-BP/IMP-1 mRNA level fell significantly, by 31 AE 12% and 36 AE 9%, in the cells transfected with CRD-BP-si1 and CRD-BP-si2 respectively, as compared with the cells treated with the control non-silencing siRNA (p < 0:05).
We investigated the effects of the CRD-BP/IMP-1 knockdown on the DNA synthesis rate in PC-3 cells. DNA synthesis was quantified by the BrdU incorporation rate into cells and corrected by the viable cell number as evaluated by MTT assay. As shown in Fig. 4B , the rate of DNA synthesis in the PC-3 cells decreased 24 h after transfection, by 24 AE 10% and 24 AE 7%, in the cells transfected with CRD-BP-si1 and CRD-BP-si2 respectively, as compared with cells treated with control siRNA (p < 0:01). After 48 h, DNA synthesis was significantly suppressed, by 39 AE 7% and 43 AE 8%, in the cells transfected with CRD-BPsi1 and CRD-BP-si2 respectively (p < 0:01). These results indicate that the CRD-BP/IMP-1 knockdown reduced the proliferation rate of the PC-3 cells.
Discussion
In this study, we found for the first time that overexpression of 8S-LOX and 15S-LOX-2 significantly down-regulated CRD-BP/IMP-1 in human prostate carcinoma PC-3 cells. A role of CRD-BP/IMP-1 in the decreased proliferation rate of PC-3 cells was shown using the specific CRD-BP/IMP-1 siRNA. Overexpression of CRD-BP/IMP-1 has been reported in a variety of human neoplasias, suggesting a crucial role of CRD-BP/ IMP-1 in cancer development. [18] [19] [20] [21] [22] 31) In fact, the knockdown of CRD-BP/IMP-1 in human breast cancer cell line MCF-7 resulted in suppression of the cell proliferation rate. 32) On the other hand, there is a report indicating that targeted knockdown of CRD-BP/IMP-1 resulted in the promotion of cell proliferation in human K562 leukemia cells. 33) Ioannidis et al. suggested that CRD-BP/IMP-1 might exert differential cell typespecific actions, and that these observations might be due to differences in CRD-BP/IMP-1 expression levels between the two cell lines. 32) Upon using a qRT-PCR methodology, the CRD-BP/IMP1-GAPDH mRNA ÁCt values for K562 and MCF-7 were calculated to be about 6 and about 14.5 respectively, indicating substantially lower CRD-BP/IMP-1 expression in MCF-7 cells. 32) Although the mRNA level in the PC-3 cells remained to be elucidated, negative signals in Northern or Western blotting suggested a low expression level for the gene. Taking all this together, a reduction in the CRD-BP/ IMP-1 mRNA level was considered to be attributable to growth inhibition of cells by 8S-LOX and 15S-LOX-2 expression in PC-3 cells. It is known that CRD-BP/ IMP-1 stabilized c-myc mRNA, 16, 19, 34) but there is a report showing that c-myc mRNA was not up-regulated in CRD-BP/IMP-1-overexpressing mammary tissues of adult transgenic mice in which mammary tumors were induced. 24) Indeed, the level of c-myc mRNA measured by qRT-PCR was not significantly reduced in PC-3 cells when RNAi was employed to silence CRD-BP/IMP-1 expression (data not shown). The mRNA level of IGF-II was reported to be increased 32, 33) or decreased 23) by down-regulation of CRD-BP/IMP-1 expression. We detected an approximately 2-fold increase in IGF-II mRNA levels after CRD-BP/IMP-1 knockdown (data not shown). It is possible that CRD-BP/IMP-1 regulated other genes promoting cell proliferation. 35) We found that growth inhibition of PC-3 cells by 8S-LOX induction was significantly more effective than that by 15S-LOX-2 expression, while the expression level of the enzyme and the specific enzyme activity were reproducibly higher in 15S-LOX-2-expressing cells than in 8S-LOX-expressing cells. With regard to this finding, the addition of arachidonic acid to the culture medium enhanced the growth inhibitory effect due to 8S-LOX and 15S-LOX-2, whereas mutated 8S-LOX that was catalytically inactive did not suppress cell growth. These results strongly suggest that arachidonate metabolites are responsible for the biological effect. The observations that linoleic acid, which was a poor substrate for these enzymes, did not affect the growth rate also agree with these findings. 26) We did not utilize LOX inhibitors because several LOX inhibitors, including nordihydroguaiaretic and eicosatetraynoic acids, were cytotoxic at concentrations at which 8S-LOX or 15S-LOX-2 activity was completely inhibited. 36, 37) 15S-HETE at more than 1 mM has been reported to be antiproliferative in PC-3 cells. 12) Although the concentration of the arachidonate metabolite in the resting cells is not known, it might be difficult for HETEs to reach the micromolar range. 38) In fact, 8S-HETE and 15S-HETE as well as 8S-HPETE, 15S-HPETE, 8S,15S-diH(P)ETE, which were generated by arachidonate metabolism with these enzymes, did not show growth inhibition up to 1 mM (data not shown). It is possible that unstable products such as 8,9-leukotriene A 4 or unidentified products might contribute to the growth inhibitory effect due to 8S-LOX and 15S-LOX-2.
8S-HETE and 15S-HETE have been reported to be ligands for PPAR-and -respectively. 10, 12, 13) PPARexpressed in PC-3 cells modulated the expression of cyclooxygenase-2 and E-cadherin when the ligand was bound. 39, 40) It remains to be elucidated whether PPARplays a direct or an indirect role in the regulation of CRD-BP/IMP-1 gene expression. Further investigation is necessary to elucidate the mechanisms of 8S-LOX and 15S-LOX-2-dependent PC-3 growth inhibition, including identification of the transcription factor that regulates CRD-BP/IMP-1 expression in the LOX-dependent manner.
